BERLIN, Germany – June 06, 2012 – In the development of novel drugs, early recognition of
potential toxicological effects and their underlying mechanisms is of utmost importance. To support the
cost- and time-effective development of new compounds with more favorable toxicological profiles,
Metanomics Health GmbH is launching MetaMap®Tox, a powerful tool for biopharmaceutical safety
research. MetaMap®Tox is a service evaluating specific metabolomic patterns in vivo, enabling
customers to better and faster identify potential safety risks of test compounds in in vivo studies of
MetaMap®Tox has been developed in-house by BASF’s Experimental Toxicology and Ecology unit
and will be marketed through Metanomics Health. Over a period of seven years, more than 500
chemical entities were thoroughly tested in vivo to generate and validate more than 100 metabolomic
fingerprints of different toxicological modes of action. These data allow for a faster and better
assessment of toxicological profiles of new chemical entities (NCEs). MetaMap®Tox thereby
addresses key unmet needs for in vivo toxicology testing: predictability, understanding of a toxicology
mechanism and the ability for translation to clinical use.
MetaMap®Tox has been technically validated by the Drug Safety Executive Council (DSEC), in a
consortium approach of twelve leading biopharmaceutical companies following the goal to advance
new technologies for the development of better and safer medicines worldwide. It will be offered in two
distinct service packages: MetaMap®Tox Screener and MetaMap®Tox Profiler.
MetaMap®Tox Screener enables lead optimization in exploratory non-GLP (Good Laboratory
Practice) tox programs based on predictive metabolomic patterns in rat plasma in 14-day studies.
Benefits include coverage of systemic toxicological profiles of NCEs and unique mechanistic
understanding based on 25 specific & predictive toxicological modes of action (MoA) in 11 different
MetaMap®Tox Profiler is targeting early safety assessment in a preclinical GLP toxicology setting.
MetaMap®Tox Profiler covers 46 validated toxicological modes of action (MoA) in a total of 17 different
target organs. Key attributes comprise the potential to detect drug side effects (e.g. liver and thyroid
injury) at an early stage and a detailed understanding of systemic toxicology of NCEs, both leading to
an improved lead selection and guidance for further toxicological tests.
“We are very happy to launch MetaMap®Tox Screener and MetaMap®Tox Profiler,” said Tim Boelke,
Managing Director of Metanomics Health. “These have been designed based on feedback by the
DSEC, whose members confirmed their great interest in a tool that provides predictive toxicological
assessments already in the exploratory non-GLP phase. We are convinced that MetaMap®Tox
addresses this key unmet need.”
“MetaMap®Tox has been developed by an interdisciplinary BASF team over a period of more than
seven years to obtain early information on the toxicological profile whilst reducing the number of
animals used,” said Bennard van Ravenzwaay, Senior Vice President, Experimental Toxicology and
Ecology at BASF. “MetaMap®Tox is already in routine use at BASF, contributing to faster decision
making and significant savings in terms of cost and time to market for the BASF Group.”
About Metanomics Health GmbH
Metanomics Health GmbH, a BASF Group company, was founded in 2003 and is a leader in robust,
non-targeted and targeted comprehensive metabolite profiling services (metabolomics) to healthcare
customers. Serving pharma, nutrition and diagnostics companies as well as academic partners, the
state-of-the-art biomedical data interpretation combined with innovative bioinformatics and data mining
systems enables discovery and validation of both simple and complex metabolomic biomarkers.
Metanomics Health delivers novel biomarkers of disease and drug efficacy, increased mechanistic
understanding of drug action and adverse effects as well as insights into underlying pathways to its
partners, thereby providing actionable results for healthcare research and development programs.
Learn more at www.metanomics-health.de
BASF is the world’s leading chemical company: The Chemical Company. Its portfolio ranges from
chemicals, plastics, performance products and crop protection products to oil and gas. We combine
economic success, social responsibility and environmental protection. Through science and innovation
we enable our customers in almost all industries to meet the current and future needs of society. Our
products and system solutions contribute to conserving resources, ensuring healthy food and nutrition
and helping to improve the quality of life. We have summed up this contribution in our corporate
purpose: We create chemistry for a sustainable future. BASF posted sales of about €73.5 billion in
2011 and had more than 111,000 employees as of the end of the year. BASF shares are traded on the
stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (AN). Further information on BASF is
available on the Internet at www.basf.com.
Contact for Business Inquiries:
Tel.: +49 (0)30-34-807-400
Contact for Media Inquiries:
Tel.: +49 (0)621-60-28574